Eli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound.
Eli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound.
